- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Synonyms :
Class :
Antimalarials; 4-Quinoline- Methanol
Dosage forms & Strengths:
Adult:
Tablet:
250 mg
Indicated to treat mild-to-moderate acute malaria due Plasmodium falciparum (chloroquine-susceptible & resistant strains both included) or by Plasmodium vivax
1250 mg orally once as a loading dose
Malaria Prevention
Indicated for the prevention of malaria
250 mg orally each week
Start over a couple of weeks before the arrival of the strain in the endemic area
Continue the medication for weeks after leaving the endemic-prone area
Dosing Consideration
If the treatment of mefloquine does not respond within 48-72 hours, stop the medication, and utilize an alternate therapy
The treatment with mefloquine in acute P.Vivax patients may cause relapse as in these patients; exoerythrocytic parasites are not eliminated
Indicated to treat mild-to-moderate acute malaria due to Plasmodium falciparum (chloroquine-susceptible & resistant strains both included) or by Plasmodium vivax
For more than 6 months, 20-25 mg/kg orally in a single dose or may be divided into 2 doses
Malaria Prevention
For 5-10 kg- 31.25 mg orally every week
10-20 kg- 62.5 mg orally every week
20-30 kg- 125 mg orally every week
30-45 kg- 187.5 mg orally every week
For more than 45 kg- 250 mg orally every week
Start over from 1-2 weeks before arrival in the endemic area
Continue upto 4 weeks after coming from endemic area
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased QTC interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mefloquine
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
the effect of mefloquine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
it decreases the effect of anti-seizure agents
1-10%:
Anxiety
Difficulty concentrating
Headache
Insomnia
Lightheadedness
Vertigo
Vomiting
Diarrhea
Stomach pain
Nausea
Visual disturbances
Tinnitus
Frequency undefined:
Suicidal depression
Psychiatric Sx
Pneumonitis
Seizure
Abnormal ECG
Mefloquine is contraindicated in people hypersensitive to it.
Pregnancy consideration:
Category B
Breastfeeding warnings:
Mefloquine is minimally excreted in human breastmilk
Pregnancy category:
Patient information leaflet
Generic Name: mefloquine
Pronounced: mef-lo-quine
Why do we use mefloquine?
Mefloquine treats acute malaria.